The chronic toxicity of clinafloxacin, a fluoroquinolone antibacterial agent, was evaluated in multiple strains of mice and rats. In 5 separate studies, mice and rats that were orally administered up to 1,000 mg/kg of clinafloxacin from 9 to 104 weeks developed doserelated cecal dilatation and deaths that were attributable to cecal torsion. Cecal rupture was observed in association with torsion. Although cecal dilatation is commonly observed in rodents given antibacterials such as fluoroquinolones, cecal torsion has not been a reported sequelae to dilatation.
INTRODUCTION
Cecal dilatation is a common finding in rodents exposed to repeated oral administration of antibiotics (3, 5, 6, 8, 9, 11) . In the absence of changes in the intestinal wall, dilatation is attributed to local antibacterial effects on the intestinal flora rather than to direct effects on the gastrointestinal tract. Dilatation of the rodent cecum as a result of the accumulation of intestinal contents, with a dose-related increase in cecal weights, has been reported for a variety of compounds (1, 4, 10, 12) . Cecal dilatation in rodents reverses when antibiotics are discontinued (8) .
However, progression to cecal torsion has not been described. Cecal torsion was identified in 5 rodent toxicity studies with clinafloxacin (CLX), a fluoroquinolone antibacterial agent.
METHODS
Animals. Three studies in mice (13 week [13W], 104 week [9W], and 26 week [26W]) and 2 studies in rats (104 week [104W] and male fertility study [92D] ) have been completed with CLX. All studies complied with US Food and Drug Administration Good Laboratory Practice regulations. Studies used B6C3F1 and CF1 mice and Wistar and Sprague-Dawley rats obtained from Charles River Laboratories (Portage, MI). The experimental designs for each study, including the number of animals per group, animal age at study initiation, and doses used, are presented in Table 1 . Rodents were housed individually in stainless-steel wire-mesh cages, provided with water ad libitum, and fed measured portions of powdered Purina Certified Rodent Chow (5002).
Compound and Dosing. Chemically, CLX is designated as 7-(3-amino-l-pyrrolidinyl)-8-chloro-l-cyclopropyl-6-fluoro-1,4-dihydro-4-oxo-3 quinoline carboxylic acid monohydrochloride. CLX was administered either as drug/diet admixture or as gavage on a milligram-per-ki-logram body weight basis. The concentration of drug in the diet was adjusted weekly according to each group's mean body weight and food consumption from the previous week. In the 92D study, the gavage vehicle used was 0.5% methylcellulose. Table 1 summarizes the experimental dose design of the studies. In the 13W study, 15 mice/sex/dose were given 0, 100, 250, 500, or 1,000 mg/kg CLX. In the 9W study, 75 mice/sex/dose were given 0, 100, 250, or 500 mg/kg for 9 weeks, at which point dosing was discontinued as a result of excessive mortality secondary to cecal torsion. In the 26W study, 25 B6C3F1 and 25 CF1 male mice (per dose) were given 0, 25, 50, 75, 100, 250, or 500 mg/kg CLX. In the rat carcinogenicity study (104W study), 55 Wistar rats/sex/ dose were given 0, 100, 250, and 500 mg/kg CLX. In a fertility and general reproduction study (92D), 40 male Sprague-Dawley rats/dose were given 0, 100, 250, or 500 mg/kg CLX by gavage daily for 75 days prior to and throughout mating with untreated females and until termination on study day 92. Clinical Observations. Animals were observed daily for signs of toxicity and mortality. Body weights and food consumption were recorded weekly. Physical examinations were performed pretest, at monthly intervals, and at study termination. Animals observed to be in distress were euthanatized.
Pathology. Animals were euthanatized by deep ether anesthesia (13W study) or by carbon dioxide asphyxiation (9W, 26W, 104W, and 92D studies). At necropsy, protocol-specified organs were weighed, and these organs included the following: in the 13W study, the intestinal tract (from pyloric sphincter to rectum, including content) and in the 104W study, the cecum (excluding contents). Organ to body weight and organ to brain weight ratios were calculated. Complete necropsies (9W, 13W, 26W, and 104W studies) were performed, and samples of all major organs, including stomach, small and large intestines, and cecum, were fixed in 10% buffered formalin, Bouin's, or 6% glutaraldehyde; embedded in paraffin; sectioned at 4 J.1m; stained with hematoxylin and eosin; Abbreviations: M = male; F = female; SD = Sprague-Dawley. and examined microscopically. In the 92D study, a gross examination was conducted on each rat. Plasma CLX Determinations. Plasma samples were collected by cardiac puncture from 5 animals per sex per group at the end of the dark cycle during the last week of the study, and these samples were evaluated for CLX concentrations.
Statistical Analyses. Body weight, food consumption, and organ weight comparisons were performed on ranktransformed data using one-factor analysis of variance (ANOVA) separately for each sex (9W and 104W studies). The one-factor ANOVA focused on a dose-trend test sequentially applied at the two-tailed 1% significance level (9W and 104W studies). From the numerical data, arithmetic means, standard deviations, or standard errors were calculated (13W study). A two-tailed Student's ttest and a probability level of 0.99 were used to identify significant differences between groups (13W study).
RESULTS

Clinical Signs, Mortality, Body Weight, and Food
Consumption
Mice. Treatment-related clinical signs and mortality attributable to cecal torsion occurred in each study ( Table  2 ). Clinical signs most commonly associated with death in mice exhibiting cecal dilatation/torsion were abdominal distension, lack of feces, ataxia, hypoactivity, and rough pelage. Less-frequent clinical signs were dehydration, soft feces, ptosis, prostration, hyperactivity, and hy-pothermia. In many cases, mortality occurred without premonitory signs.
In the 13W study, early deaths as a result of cecal torsion included 1 male at 100 mg/kg, 4 males at 500 mg/kg, and 1 male and 1 female at 1,000 mg/kg during weeks 10 to 13. There were no clear effects of treatment on body weight or food consumption.
In the 9W study, dosing was discontinued after week 9 because of excessive mortality as a result of cecal torsion. Surviving animals were given control diet for the remainder of the 104-week study. At 500 mg/kg, 1 male mouse died during week 2 secondary to cecal torsion, whereas the majority of deaths in males at all doses occurred during weeks 5 to 10. The majority of deaths in females at 250 and 500 mg/kg occurred during weeks 9 and 10. Mortality due to cecal torsion during the first 10 weeks was 0, 19, 28, and 25% in males and 0, 3, 8, and 4 in females at 0, 100, 250, and 500 mg/kg, respectively. Cecal torsion was not observed after week 11, within 2 weeks after dosing cessation. During the 9-week course of dosing, drug-related effects on body weight and food consumption did not occur.
The 26W study (Table 3 ) was designed to compare mouse strain susceptibility to CLX-associated cecal torsion. At the highest doses of 250 and 500 mg/kg, deaths that were attributable to cecal torsion in B6C3F1 mice occurred during week 2 and later in the study, with 19 deaths at 250 mg/kg and 22 deaths at 500 mg/kg. Only three 250 mg/kg and two 500 mg/kg mice survived until distention due to cecal dilatation was noted in 0, 7, 27, and 65% in males and in 3, 40, 64, and 71% in females at 0, 100, 250, and 500 mg/kg, respectively. One female at 100 mg/kg and 10 males and 3 females at 500 mg/kg died from cecal torsion during weeks 66 to 101. Relative to controls, mean body weights for all male CLX-treatment groups were decreased by less than 10% throughout most of the study. For female CLX-treatment groups, dose-related decreases in body weights were noted beginning at approximately week 44. By week 76, mean body weights for females were decreased 7, 15, and 21 % at 100, 250, and 500 mg/kg, respectively, relative to controls, and body weights remained relatively constant during the remainder of the study. Over the entire study pe-riod, weight gain for surviving females was decreased 11, 23, and 35% at 100, 250, and 500 mg/kg, respectively. There were no effects on food consumption in male rats. From week 18 to week 104, decreased food consumption in females ranged from 4 to 9% at 250 mg/kg and from 5 to 15% at 500 mg/kg. In the fertility and general reproduction study in male rats (92D), cecal torsion caused death in 3, 13, and 15% of rats given 100, 250, and 500 mg/kg CLX, respectively, between days 55 and 92. At termination, abdominal distention was present in 0, 3, 25, and 35% of males at 0, 100, 250, and 500 mg/kg, respectively. Mean body weight at 100 mg/kg was comparable to vehicle control throughout the 92-day treatment period. At 250 and 500 mg/kg, mean body weights were within 4 to 13% of vehicle controls from treatment days 7 through 92. Mean body weight gain during the premating period (days 0-75) was statistically significantly reduced; this measure was approximately 30 and 40% at 250 and 500 mg/kg, respectively. At 500 mg/kg, total food consumption was statistically significantly reduced by approximately 5% relative to vehicle controls during the premating period and was approximately 11 % lower than vehicle controls during the postmating period.
Pathology
Mice. In the 13W study, the 7 early-death mice displayed markedly congested ceca associated with torsion of the cecum at the ileocecocolic junction. In 3 mice the twisted cecum had ruptured and expelled blood-tinged intestinal contents into the peritoneal cavity. Histopathologically, those mice that died had diffuse cecal hemorrhagic necrosis. Gram-stained sections of control and treated ceca demonstrated that control ceca had predominantly long filamentous gram-positive bacteria with a few gram-negative bacilli. In treated mice, flora consisted of a mixture of gram-positive and gram-negative short bacilli that appeared in substantially smaller numbers when compared to those numbers associated with controls. At termination, statistically significant increases in intestinal weights (pyloric sphincter to rectum) and ratios were present in all treated groups of both sexes (Table  4 ). At termination, dilatation and torsion of the cecum, with no signs of vascular compromise, were seen in 29 and 22% of males at 500 and 1,000 mg/kg, respectively. FIGURE Cecal torsion in a male B6C3F, mouse given 500 mg/kg clinafloxacin for 9 weeks. Left dorsally displaced deeply congested cecum is distended with fluid and gas and has multiple twists at base of cecum (arrow). -Cecal torsion in a male Sprague-Dawley rat given 500 mg/kg clinafloxacin for 92 days. There are multiple twists (arrow) around the ileocecocolic junction with hemorrhagic necrosis of cecum and gaseous distension of loops of small intestines. mural thinning of the intestinal wall were present with no significant histopathologic alteration of mucosa, submucosa, or muscularis.
At termination, dilatation of the cecal lumen and trans-
In the 9W study, drug-related pathologic changes at necropsy were observed in the intestinal tract at all doses during the first 11 weeks of the study. Commonly, the base of the cecum was twisted clockwise around the ileocecocolic junction when viewed from the ventral aspect. The apex of the hemorrhagic cecum was pointing cranial in the anterior left quadrant of the abdomen, reflecting the rotation of > 360°, with multiple twists around the base of the cecum (Figure 1 ). Some mice had up to 6 twists around the ileocecocolic junction. Cecal contents were watery dark red-brown to black, and serosa was deeply congested. Ceca were ruptured in 3 males at 100 and 250 mg/kg each, and ceca were ruptured in 4 males at 500 mg/kg. Microscopically torsed ceca had transmural necrosis, hemorrhage, edema, and inflammatory cell infiltrates (Figure 2 ). Abdominal viscera and parietal peritoneum of animals with cecal torsion had hemorrhage and inflammatory infiltrates. Ceca of mice dying after 11 weeks and at termination were normal.
In the 26W study designed to compare susceptibility of different mouse strains, incidence of cecal dilatation was similar in both strains, and severity of dilatation was dose related, as follows: minimal to mild at 25 and 50 mg/kg, mild to moderate at 75 and 100 mg/kg, and mild to marked at 250 and 500 mg/kg. Cecal torsion was much more common, occurred earlier, and occurred at lower doses in B6C3F1 mice than in CF1 mice . (Table 3 ). In B6C3F1 mice, 1 mouse at 250 mg/kg and 3 mice at 500 mg/kg had ruptured ceca. In CF1 mice, at 250 mg/kg, 1 mouse had cecal torsion at terminal necropsy, and at 500 mg/kg, 1 death was due to cecal torsion, and 3 mice had cecal torsions at terminal necropsy.
Rats. In the 104W study, cecal torsion was found at necropsy after 66 weeks of treatment in 1 female at 100 mg/kg (2%) and in 10 males (18%) and 3 females (5%) at 500 mg/kg. Cecal torsion was the leading cause of death in males at 500 mg/kg, accounting for 33% of all weight and ratios in rats given clinafloxacin in the diet for 104 weeks (values expressed as mean -standard error).
Abbreviations: M = male; F = female. * Mean value significantly different from control mean at 1 % level by sequential trend test within one-factor analysis of variance. deaths. Microscopically, there was cecal transmural necrosis, hemorrhage, edema, and vascular thrombosis (Figure 3) . At termination, washed cecal weights and ratios were statistically significantly increased in all treated groups of both sexes ( Table 5 ). Significant treatment-related gross pathologic changes were limited to the intestinal tract. The incidence of cecal dilatation was 0, 38, 74, and 100% in males and 0, 16, 88, and 100% in females at 0, 100, 250, and 500 mg/kg, respectively. Cecal torsion was found at termination in one 500 mg/kg male (4%). Microscopically, in rats with cecal dilatation, cecal muscularis was thinned, and the mucosa appeared normal.
In the general reproduction study in male rats (92D), cecal dilatation was dose related in severity and was observed in all treated males at termination. Dilatation of the colon or diffuse dilatation of the large intestine was seen in 10 and 13% of rats given 250 and 500 mg/kg, respectively. Cecal torsion occurred in 3, 13, and 15% of rats given 100, 250, and 500 mg/kg, respectively. As was the case in the mice, rat ceca had multiple twists at the ileocecocolic junction, with gaseous distension of the loops of the small intestines ( Figure 4 ).
Plasma Drug Concentrations
Mice. In the 13W study, plasma CLX concentrations at the end of the dark cycle in week 13 increased with increasing dose and were similar in males and females. At 100, 250, 500, and 1,000 mg/kg, mean drug concentrations were 0.20 ± 0.03, 0.34 ± 0.05, 0.78 ± 0.30, and 1.22 ± 0.33 )JLg/ml in males and 0.21 ± 0.01, 0.54 ± 0.14, 1.25 -~-0.44, and 2.74 ± 1.22 )JLg/ml in females, respectively. In the 9W study, plasma CLX concentrations 2 hours after the end of the dark cycle in week 9 were highly variable and were not dose related. Mean drug concentrations were below the quantitation limit (0.10 [Lg/ml) in males at 100 and 500 mg/kg, and the mean drug concentration level was 0.16 ± 0.05 >g/ml at 250 mg/kg. In females, mean drug concentrations were 0.02 ± 0.05, 0.17 ± 0.14, and 0.43 ± 0.27 J.1g/ml at 100, 250, and 500 mg/kg, respectively.
In the 26W study, there were no strain differences in plasma CLX concentrations. Plasma concentrations at 100 mg/kg were consistently below the quantitation limits of the assay. Mean plasma CLX concentrations were 0.257 ± 0.043 and 0.734 >g/ml in B6C3F, mice and 0.423 ± 0.266 and 0.713 ± 0.255 )JLg/ml in CF1 mice at 250 and 500 mg/kg, respectively (Table 3) .
Rats. In the 104W study, mean CLX plasma concentrations increased with increasing dose and were similar during weeks 53 and 104. At the end of the dark cycle during week 104, mean drug concentrations in males were 1.03 ± 0.37, 2.56 ± 0.52, and 6.65 ± 1.78 Rg/ml at 100, 250, and 500 mg/kg, respectively, and in females, mean drug concentrations were 0.95 ± 0.27 and 5.00 ± 0.78 at 100 and 500 mg/kg, respectively.
DISCUSSION
The cecum of the mouse and rat is a blind pouch from which the colon and ileum exit in close proximity and in which antiperistaltic movements occur (2) . This structure and the presence of bacteria contribute to the cecum's ability to function as a fermentation organ in which breakdown of ingesta can occur in a reasonably controlled milieu (2) . The rodent cecum is predisposed to torsion because of its lack of mesenteric anchorage and potential mobility within the rodent abdomen. Deaths attributable to spontaneous cecal torsion have been reported to occur occasionally in adult guinea pigs. At necropsy, the displaced cecum was distended with fluid and gas; the intestinal wall was edematous and hemorrhagic (7) . Torsion of the cecum in rodents given CLX occurred because of marked cecal distension (by abnormally fluid contents) and perhaps because of hypermotility, which caused the cecum to rotate on its longitudinal axis at the ileocecocolic junction.
Oral administration of a wide variety of compounds, such as raw and chemically modified starches, caramels, sugar alcohols (lactitol, sorbitol, mannitol, and xylilol), lactose, a synthetic polydextrose, polythylene glycol, and magnesium sulfate, to rats has been associated with an increase in cecal size (1, 2, 4, 10, 12) . Cecal dilatation appears to be generally related to the osmotic activity of the cecal contents in rodents treated with these compounds, and it has been postulated that the changes represent a physiological adaptation to increased osmotic forces, regardless of the contributing compound (2, 4) .
Treatment of rodents with antibiotics also causes cecal dilatation without significant histopathologic changes as a result of changes in cecal bacterial flora (2, 3, 5, 6, 8., 9, 11) . The microflora in enlarged ceca from mice administered penicillin in drinking water for 30 days was qualitatively different from that of controls: no lactobacilli or group N streptococci were cultured, and no fusiform bacteria were seen in histologic sections (8) . Flora consisted primarily of lactose-fermenting coliforms, Klebsiella-Aerobacter types, enterococci, and clostridia (8) . A dose-related statistically significant increase in cecal weights has been reported in rats following treatment for 6 months with pipemidic acid (9) .
The cecal dilatation seen in mice and rats treated with CLX was an anticipated class effect. CLX treatment altered the normal catabolizing flora, which resulted in dose-dependent degrees of cecal dilatation. Lower doses of CLX induced minimal to mild cecal dilatation, whereas higher doses and chronic administration induced moderate to marked cecal dilatation. Cecal dilatation resulted in dose-dependent increases in intestinal and cecal weights. In the 13W mouse study, the increase in intestinal weights and ratios was due to distension of the cecum, with increased amounts of abnormal intestinal contents and no increase in tissue weight, as evidenced microscopically by transmural thinning of normal-appearing cecal wall. In the 104W rat study, washed cecal weights increased with increasing dose; however, microscopically, the ceca appeared normal. At the higher doses of CLX, the markedly dilated ceca (filled with abnormal ingesta) predisposed the rodent cecum to torsion. The histopathology of cecal hemorrhagic necrosis was indicative of vascular compromise following torsion. The incidence of cecal torsion was higher in males and occurred earlier than in females. Male Sprague-Dawley rats developed CLX-associated cecal torsion, whereas female Sprague-Dawley rats at similar doses and treatment periods did not (data not shown). The CF1 mouse strain appeared to be more tolerant than the B6C3F1 mice with regard to CLX-associated cecal torsion, even at similar plasma concentrations. Progression of cecal dilatation to torsion has not been reported. Based on findings from our studies, cecal torsion is a possible sequelae to chronic administration of fluoroquinolone antibacterials in rodents.
